{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T02:01:30Z","timestamp":1793239290594,"version":"4.5.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T00:00:00Z","timestamp":1710720000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T00:00:00Z","timestamp":1710720000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Metab"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Metformin, a widely used first-line treatment for type 2 diabetes (T2D), is known to reduce blood glucose levels and suppress appetite. Here we report a significant elevation of the appetite-suppressing metabolite\n                    <jats:italic>N<\/jats:italic>\n                    -lactoyl phenylalanine (Lac-Phe) in the blood of individuals treated with metformin across seven observational and interventional studies. Furthermore, Lac-Phe levels were found to rise in response to acute metformin administration and post-prandially in patients with T2D or in metabolically healthy volunteers.\n                  <\/jats:p>","DOI":"10.1038\/s42255-024-01018-7","type":"journal-article","created":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T07:02:25Z","timestamp":1710745345000},"page":"651-658","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":83,"title":["Metformin and feeding increase levels of the appetite-suppressing metabolite Lac-Phe in humans"],"prefix":"10.1038","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8841-3525","authenticated-orcid":false,"given":"Barry","family":"Scott","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3245-5715","authenticated-orcid":false,"given":"Emily A.","family":"Day","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie L.","family":"O\u2019Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-9559-4731","authenticated-orcid":false,"given":"John","family":"Scanlan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Cromwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aine Ni","family":"Scannail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie E.","family":"McDonnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2716-6679","authenticated-orcid":false,"given":"David K.","family":"Finlay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4273-4681","authenticated-orcid":false,"given":"Lydia","family":"Lynch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,18]]},"reference":[{"key":"1018_CR1","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1007\/s00125-013-2991-0","volume":"56","author":"G Rena","year":"2013","unstructured":"Rena, G., Pearson, E. R. & Sakamoto, K. Molecular mechanism of action of metformin: old or new insights? Diabetologia 56, 1898\u20131906 (2013).","journal-title":"Diabetologia"},{"key":"1018_CR2","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1038\/s41574-023-00833-4","volume":"19","author":"M Foretz","year":"2023","unstructured":"Foretz, M., Guigas, B. & Viollet, B. Metformin: update on mechanisms of action and repurposing potential. Nat. Rev. Endocrinol. 19, 460\u2013476 (2023).","journal-title":"Nat. Rev. Endocrinol."},{"key":"1018_CR3","doi-asserted-by":"publisher","first-page":"731","DOI":"10.2337\/dc11-1299","volume":"35","author":"Diabetes Prevention Program Research Group.","year":"2012","unstructured":"Diabetes Prevention Program Research Group. Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care 35, 731\u2013737 (2012).","journal-title":"Diabetes Care"},{"key":"1018_CR4","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1002\/j.1550-8528.1998.tb00314.x","volume":"6","author":"A Lee","year":"1998","unstructured":"Lee, A. & Morley, J. E. Metformin decreases food consumption and induces weight loss in subjects with obesity with type II non-insulin-dependent diabetes. Obes. Res. 6, 47\u201353 (1998).","journal-title":"Obes. Res."},{"key":"1018_CR5","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1210\/endrev\/bnaa023","volume":"42","author":"TE LaMoia","year":"2021","unstructured":"LaMoia, T. E. & Shulman, G. I. Cellular and molecular mechanisms of metformin action. Endocr. Rev. 42, 77\u201396 (2021).","journal-title":"Endocr. Rev."},{"key":"1018_CR6","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1007\/s00125-008-1053-5","volume":"51","author":"CJ Bailey","year":"2008","unstructured":"Bailey, C. J., Wilcock, C. & Scarpello, J. H. B. Metformin and the intestine. Diabetologia 51, 1552\u20131553 (2008).","journal-title":"Diabetologia"},{"key":"1018_CR7","doi-asserted-by":"crossref","unstructured":"Salpeter, S. R., Greyber, E., Pasternak, G. A. & Salpeter, E. E. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst. Rev. 2010, CD002967 (2010).","DOI":"10.1002\/14651858.CD002967.pub4"},{"key":"1018_CR8","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1007\/s40261-017-0564-6","volume":"37","author":"W Huang","year":"2017","unstructured":"Huang, W., Castelino, R. L. & Peterson, G. M. Lactate levels with chronic metformin use: a narrative review. Clin. Drug Investig. 37, 991\u20131007 (2017).","journal-title":"Clin. Drug Investig."},{"key":"1018_CR9","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1002\/cpt.2382","volume":"110","author":"N Rittig","year":"2021","unstructured":"Rittig, N. et al. Metformin stimulates intestinal glycolysis and lactate release: a single-dose study of metformin in patients with intrahepatic portosystemic stent. Clin. Pharmacol. Ther. 110, 1329\u20131336 (2021).","journal-title":"Clin. Pharmacol. Ther."},{"key":"1018_CR10","doi-asserted-by":"publisher","first-page":"e2211933120","DOI":"10.1073\/pnas.2211933120","volume":"120","author":"N Tobar","year":"2023","unstructured":"Tobar, N. et al. Metformin acts in the gut and induces gut\u2013liver crosstalk. Proc. Natl Acad. Sci. USA 120, e2211933120 (2023).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1018_CR11","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1038\/s42255-019-0146-4","volume":"1","author":"EA Day","year":"2019","unstructured":"Day, E. A. et al. Metformin-induced increases in GDF15 are important for suppressing appetite and promoting weight loss. Nat. Metab. 1, 1202\u20131208 (2019).","journal-title":"Nat. Metab."},{"key":"1018_CR12","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1038\/s41586-019-1911-y","volume":"578","author":"AP Coll","year":"2020","unstructured":"Coll, A. P. et al. GDF15 mediates the effects of metformin on body weight and energy balance. Nature 578, 444\u2013448 (2020).","journal-title":"Nature"},{"key":"1018_CR13","doi-asserted-by":"publisher","first-page":"111258","DOI":"10.1016\/j.celrep.2022.111258","volume":"40","author":"AB Klein","year":"2022","unstructured":"Klein, A. B. et al. The GDF15-GFRAL pathway is dispensable for the effects of metformin on energy balance. Cell Rep. 40, 111258 (2022).","journal-title":"Cell Rep."},{"key":"1018_CR14","doi-asserted-by":"crossref","unstructured":"Jansen, R. S. et al. N-lactoyl-amino acids are ubiquitous metabolites that originate from CNDP2-mediated reverse proteolysis of lactate and amino acids. Proc. Natl Acad. Sci. USA 112, 6601\u20136606 (2015).","DOI":"10.1073\/pnas.1424638112"},{"key":"1018_CR15","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1038\/s41586-022-04828-5","volume":"606","author":"VL Li","year":"2022","unstructured":"Li, V. L. et al. An exercise-inducible metabolite that suppresses feeding and obesity. Nature 606, 785\u2013790 (2022).","journal-title":"Nature"},{"key":"1018_CR16","doi-asserted-by":"publisher","first-page":"e136055","DOI":"10.1172\/JCI136055","volume":"131","author":"R Sharma","year":"2021","unstructured":"Sharma, R. et al. Circulating markers of NADH-reductive stress correlate with mitochondrial disease severity. J. Clin. Invest. 131, e136055 (2021).","journal-title":"J. Clin. Invest."},{"key":"1018_CR17","doi-asserted-by":"publisher","unstructured":"Li, P. et al. Systems analysis of metabolic responses to a mixed meal test in an obese cohort reveals links between tissue metabolism and the gut microbiota. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2022.04.26.489057 (2022).","DOI":"10.1101\/2022.04.26.489057"},{"key":"1018_CR18","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1017\/thg.2012.89","volume":"16","author":"A Moayyeri","year":"2013","unstructured":"Moayyeri, A., Hammond, C. J., Hart, D. J. & Spector, T. D. The UK Adult Twin Registry (TwinsUK Resource). Twin Res. Hum. Genet. 16, 144\u2013149 (2013).","journal-title":"Twin Res. Hum. Genet."},{"key":"1018_CR19","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1007\/s00125-019-4872-7","volume":"62","author":"LC Gormsen","year":"2019","unstructured":"Gormsen, L. C. et al. Metformin increases endogenous glucose production in non-diabetic individuals and individuals with recent-onset type 2 diabetes. Diabetologia 62, 1251\u20131256 (2019).","journal-title":"Diabetologia"},{"key":"1018_CR20","doi-asserted-by":"publisher","first-page":"705932","DOI":"10.3389\/fphar.2021.705932","volume":"12","author":"LA Dahabiyeh","year":"2021","unstructured":"Dahabiyeh, L. A. et al. A metabolic pattern in healthy subjects given a single dose of metformin: a metabolomics approach. Front. Pharmacol. 12, 705932 (2021).","journal-title":"Front. Pharmacol."},{"key":"1018_CR21","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1016\/S0140-6736(22)02033-5","volume":"400","author":"S Urva","year":"2022","unstructured":"Urva, S. et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet 400, 1869\u20131881 (2022).","journal-title":"Lancet"},{"key":"1018_CR22","doi-asserted-by":"publisher","first-page":"bvab118","DOI":"10.1210\/jendso\/bvab118","volume":"5","author":"RB Vega","year":"2021","unstructured":"Vega, R. B. et al. A metabolomic signature of glucagon action in healthy individuals with overweight\/obesity. J. Endocr. Soc. 5, bvab118 (2021).","journal-title":"J. Endocr. Soc."},{"key":"1018_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-72914-7","volume":"10","author":"I Agueusop","year":"2020","unstructured":"Agueusop, I., Musholt, P. B., Klaus, B., Hightower, K. & Kannt, A. Short-term variability of the human serum metabolome depending on nutritional and metabolic health status. Sci. Rep. 10, 16310 (2020).","journal-title":"Sci. Rep."},{"key":"1018_CR24","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1007\/s00125-021-05477-5","volume":"64","author":"T Moholdt","year":"2021","unstructured":"Moholdt, T. et al. The effect of morning vs evening exercise training on glycaemic control and serum metabolites in overweight\/obese men: a randomised trial. Diabetologia 64, 2061\u20132076 (2021).","journal-title":"Diabetologia"},{"key":"1018_CR25","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.jff.2018.08.037","volume":"49","author":"S Mathew","year":"2018","unstructured":"Mathew, S. et al. Metabolic changes of the blood metabolome after a date fruit challenge. J. Funct. Foods 49, 267\u2013276 (2018).","journal-title":"J. Funct. Foods"},{"key":"1018_CR26","doi-asserted-by":"publisher","unstructured":"Xiao, S. et al. Lac-Phe mediates the effects of metformin on food intake and body weight. Nat. Metab. https:\/\/doi.org\/10.1038\/s42255-024-00999-9 (2024).","DOI":"10.1038\/s42255-024-00999-9"},{"key":"1018_CR27","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.cmet.2018.09.022","volume":"29","author":"ET Cirulli","year":"2019","unstructured":"Cirulli, E. T. et al. Profound perturbation of the metabolome in obesity is associated with health risk. Cell Metab. 29, 488\u2013500.e2 (2019).","journal-title":"Cell Metab."},{"key":"1018_CR28","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1002\/oby.23141","volume":"29","author":"KL Whytock","year":"2021","unstructured":"Whytock, K. L. et al. Prolonged glucagon infusion does not affect energy expenditure in individuals with overweight\/obesity: a randomized trial. Obesity 29, 1003\u20131013 (2021).","journal-title":"Obesity"},{"key":"1018_CR29","doi-asserted-by":"publisher","first-page":"6656","DOI":"10.1021\/ac901536h","volume":"81","author":"AM Evans","year":"2009","unstructured":"Evans, A. M., DeHaven, C. D., Barrett, T., Mitchell, M. & Milgram, E. Integrated, nontargeted ultrahigh performance liquid chromatography\/electrospray ionization tandem mass spectrometry platform for the identification and relative quantification of the small-molecule complement of biological systems. Anal. Chem. 81, 6656\u20136667 (2009).","journal-title":"Anal. Chem."},{"key":"1018_CR30","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1093\/jalm\/jfz026","volume":"5","author":"L Ford","year":"2020","unstructured":"Ford, L. et al. Precision of a clinical metabolomics profiling platform for use in the identification of inborn errors of metabolism. J. Appl. Lab. Med. 5, 342\u2013356 (2020).","journal-title":"J. Appl. Lab. Med."},{"key":"1018_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/1758-2946-2-9","volume":"2","author":"CD DeHaven","year":"2010","unstructured":"DeHaven, C. D., Evans, A. M., Dai, H. & Lawton, K. A. Organization of GC\/MS and LC\/MS metabolomics data into chemical libraries. J. Cheminform. 2, 9 (2010).","journal-title":"J. Cheminform."}],"container-title":["Nature Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s42255-024-01018-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42255-024-01018-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42255-024-01018-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T21:03:17Z","timestamp":1714165397000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s42255-024-01018-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,18]]},"references-count":31,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,4]]}},"alternative-id":["1018"],"URL":"https:\/\/doi.org\/10.1038\/s42255-024-01018-7","relation":{},"ISSN":["2522-5812"],"issn-type":[{"value":"2522-5812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,18]]},"assertion":[{"value":"23 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"B.S. is due to undertake a 3-month internship at Metabolon as part of his PhD. L.L. is a member of the scientific advisory board for MiNK Therapeutics and Faeth Therapeutics. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}